PrEP acceptable to gay men and few report that it would change their risk behaviour
Poor CD4 cell recovery after starting HIV treatment should be a cause for concern, close monitoring needed
Boceprevir response and resistance differs according to HCV genotype 1 subtype
Herpes drugs and viral load: valaciclovir works better than aciclovir
Valaciclovir slows HIV disease progression in pregnant and breastfeeding women
New integrase inhibitor dolutegravir looks potent and well-tolerated
High levels of unmet need for family planning in people with HIV - couples unaware of conception and contraception options
Infant prophylaxis during breastfeeding reduces risk of HIV infection by 71%
What's next for HIV prevention? Paying people to be healthy
Another NRTI-sparing regimen does well in treatment-naive patients
Gay men’s PrEP study final results: near 90% efficacy in men who took drug, but adherence even lower than thought
